2024-513550-30-00招募中3 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58)
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 280
- 试验地点
- 31
- 主要终点
- OS
研究概览
简要总结
To compare overall survival (OS) for subjects treated with Optune concomitant with maintenance temozolomide (TMZ) plus pembrolizumab versus those treated with Optune concomitant with maintenance TMZ plus placebo
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •The participant (or legally acceptable representative) has provided documented informed consent for the study.
- •Life expectancy ≥ 3 months.
- •Stable or decreasing dose of corticosteroids (dexamethasone ≤ 2mg or equivalent) for the last 7 days prior to randomization, if applicable.
- •For the full list of inclusion criteria, please refer to the protocol.
- •Be ≥ 18 years of age on day of providing informed consent.
- •Participant with new diagnosis of GBM according to WHO 2021 Classification.
- •Recovered from maximal debulking surgery (gross total resection, partial resection and biopsy-only patients are all acceptable), Gliadel wafers placement at the time of surgical resection is not allowed.
- •Have completed standard adjuvant chemoradiotherapy of RT according to local practice (56-64 Gy), and concomitant TMZ chemotherapy.
- •Able to start treatment between 4 to 7 weeks from the later of last dose of concomitant temozolomide or radiotherapy.
- •Amenable to treatment with Optune concomitant with maintenance temozolomide (150-200 mg/m^2 daily x 5, Q28 days).
- •All patients must have had tissue submitted for MGMT Promoter Methylation determination prior to randomization.
- •Have an ECOG Performance Status of 0 to 1 assessed within 7 days before randomization.
排除标准
- •Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
- •Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- •Has an active infection requiring systemic therapy.
- •Has a known history of human immunodeficiency virus (HIV), Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection Note: Hepatitis B and C screening tests are not required unless: - Known history of HBV and HCV infection - As mandated by local health authority
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
- •Has a known psychiatric or substance abuse disorder that would interfere with the participant’s ability to cooperate with the requirements of the study.
- •Has had an allogenic tissue/solid organ transplant.
- •Early progressive disease after the end of TMZ/RT. If pseudoprogression is suspected, additional imaging studies should be performed to rule out true progression.
- •Infratentorial or leptomeningeal disease.
- •Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.
- •A skull defect (such as, missing bone with no replacement) or bullet fragments.
- •Ongoing requirement for >2 mg dexamethasone (or equivalent), due to intracranial mass effect.
- •Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness).
- •Known allergies to medical adhesives or hydrogel and/or compounds of similar chemical or biologic composition to Temozolomide.
- •Admitted to an institution by administrative or court order.
- •Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to randomization. Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible. Note: If the participant had a major operation, the participant must have recovered adequately from the procedure and/or any complications from the operation before starting study intervention.
- •Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed. Refer to Section 6.5.1 for information on COVID-19 vaccines
- •Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first study treatment. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication.
- •Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
- •Has severe hypersensitivity (≥Grade 3) to the experimental drug and/or any of its excipients.
- •Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
结局指标
主要结局
OS
OS
次要结局
- 1. PFS per RANO 2.0 as assessed by investigator
- 2. PFS per RANO as assessed by investigator
- 3. PFS6m and PFS12m per RANO 2.0 as assessed by investigator
- 4. PFS2 per RANO 2.0 as assessed by investigator
- 5. 1- and 2-year survival rates
- 6. The EORTC QLQ-C30 with BN20 module score
- 7. Subjects experiencing AEs
研究者
Novocure Medical Information
Scientific
Novocure GmbH
研究点 (31)
Loading locations...
相似试验
招募中
3 期
Extension Study for Participants in Studies That Include Pembrolizumab2022-501254-10-00Merck Sharp & Dohme LLC1,133
已完成
4 期
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis2023-504869-23-00AbbVie Deutschland GmbH & Co. KG272
招募中
3 期
A study to evaluate the efficacy and safety of Clascoterone solution in treatment of male pattern hair loss.Androgenetic Alopecia2023-504421-39-00Cassiopea S.p.A.629
招募中
2 期
LSTA1 for subjects with newly diagnosed Glioblastoma Multiforme when added to standard of care (temozolomide) versus temozolomideGlioblastoma Multiforme2023-506813-23-00Tartu University Hospital30
招募中
2 期
Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX7272024-516293-29-01Taiho Oncology Inc.79